Status: Recruiting
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and elevated Lp(a).
Participants needed: 204
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Kylonova (Xiamen) Biopharma co., LTD.Updated: Jun 25, 2026Locations: 59
Eligibility criteria
Age 18 to 80 years [+2]
Have moderate to severe heart failure (New York Heart Association [NYHA] Functio... [+4]